PCSK9 and cancer: This rigorous investigation resulted in the approval of three mAbs and one siRNA agent that can obstruct both intracellular and extracellular PCSK9 function.441 In this segment, we consolidate the existing approaches developed to inhibit PCSK9 in the context of cancer treatment.